|
US7070782B1
(en)
|
1992-11-05 |
2006-07-04 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
|
US6953668B1
(en)
|
1992-11-05 |
2005-10-11 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
WO1996026272A1
(en)
|
1995-02-24 |
1996-08-29 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
US6569432B1
(en)
|
1995-02-24 |
2003-05-27 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
US7381407B1
(en)
|
1996-03-25 |
2008-06-03 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6150508A
(en)
*
|
1996-03-25 |
2000-11-21 |
Northwest Biotherapeutics, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6962981B1
(en)
|
1996-03-25 |
2005-11-08 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
|
US6207805B1
(en)
|
1997-07-18 |
2001-03-27 |
University Of Iowa Research Foundation |
Prostate cell surface antigen-specific antibodies
|
|
GB2328871A
(en)
*
|
1997-09-05 |
1999-03-10 |
Merck & Co Inc |
Compositions for inhibiting platelet aggregation
|
|
AU3305699A
(en)
*
|
1998-02-26 |
1999-09-15 |
Beckman Coulter, Inc. |
Prostate-specific membrane antigens and methods of making and using
|
|
DE69941187D1
(de)
*
|
1998-06-01 |
2009-09-10 |
Agensys Inc |
Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen
|
|
US20030035798A1
(en)
*
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
|
SE9900495D0
(sv)
*
|
1999-02-12 |
1999-02-12 |
Pharmatrix Ab |
Vaccine composition
|
|
WO2000050457A1
(en)
*
|
1999-02-22 |
2000-08-31 |
Beckman Coulter, Inc. |
Prostate-specific membrane antigens and methods of making and using
|
|
ES2277846T3
(es)
*
|
1999-07-29 |
2007-08-01 |
Medarex, Inc. |
Anticuerpos monoclonales humanos para antigeno prostatico especifico.
|
|
EP1710256A1
(en)
*
|
1999-07-29 |
2006-10-11 |
Medarex, Inc. |
Human monoclonal antibodies to prostate specific membrane antigen
|
|
FR2797743B1
(fr)
*
|
1999-08-23 |
2003-08-08 |
Urogene |
Lignee cellulaire prostatique et son utilisation pour l'obtention d'une tumeur prostatique etablie chez l'animal
|
|
US6653129B1
(en)
*
|
1999-09-13 |
2003-11-25 |
The Regents Of The University Of Colorado |
Method for isolation of cells from a solution
|
|
JP4838436B2
(ja)
*
|
2001-04-04 |
2011-12-14 |
積水メディカル株式会社 |
抗ヒト肝性トリグリセリドリパーゼ抗体
|
|
US7514078B2
(en)
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
|
CA2447695C
(en)
|
2001-06-01 |
2015-02-24 |
Cornell Research Foundation, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
|
IL159422A0
(en)
|
2001-09-20 |
2004-06-01 |
Cornell Res Foundation Inc |
Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
US20040161776A1
(en)
*
|
2001-10-23 |
2004-08-19 |
Maddon Paul J. |
PSMA formulations and uses thereof
|
|
WO2003034903A2
(en)
*
|
2001-10-23 |
2003-05-01 |
Psma Development Company, L.L.C. |
Psma antibodies and protein multimers
|
|
ES2314272T3
(es)
|
2003-01-10 |
2009-03-16 |
Millennium Pharmaceuticals, Inc. |
Metodos para el diagnostico y el tratamiento del cancer.
|
|
CA2598454C
(en)
|
2005-02-18 |
2013-04-09 |
Medarex, Inc. |
Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
|
|
EP3300739A3
(en)
*
|
2005-03-31 |
2018-07-18 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161p2f10b proteins
|
|
EP1726650A1
(en)
*
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
EP1934261B1
(en)
|
2005-09-26 |
2014-10-29 |
Medarex, L.L.C. |
Human monoclonal antibodies to cd70
|
|
ATE509033T1
(de)
|
2006-03-20 |
2011-05-15 |
Univ California |
Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
|
|
US8940298B2
(en)
|
2007-09-04 |
2015-01-27 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
|
|
JP5286370B2
(ja)
*
|
2008-02-29 |
2013-09-11 |
アイメック |
細胞酵素ベースのバイオセンサ
|
|
EP2326350B1
(en)
|
2008-09-08 |
2013-09-04 |
Psma Development Company, L.L.C. |
Compounds for killing psma-expressing, taxane-resistant cancer cells
|
|
JP5906090B2
(ja)
|
2009-02-17 |
2016-04-20 |
コーネル・リサーチ・ファンデーション・インコーポレイテッドＣｏｒｎｅｌｌ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃｏｒｐｏｒａｔｅｄ |
癌の診断のための方法およびキットならびに治療価の推定
|
|
CA3040276A1
(en)
|
2009-12-02 |
2011-06-09 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
|
SG194567A1
(en)
|
2011-04-21 |
2013-12-30 |
Seattle Genetics Inc |
Novel binder-drug conjugates (adcs) and their use
|
|
BR112013027224A8
(pt)
|
2011-04-22 |
2018-08-14 |
Emergent Product Dev Seattle |
Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
|
|
AU2014372833B2
(en)
|
2013-12-23 |
2019-08-22 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
|
|
SG11201710639YA
(en)
|
2015-06-22 |
2018-01-30 |
Bayer Pharma AG |
Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
CN108136012B
(zh)
|
2015-08-07 |
2022-10-04 |
伊麦吉纳博公司 |
靶向分子的抗原结合构建体
|
|
HK1251480A1
(zh)
|
2015-09-21 |
2019-02-01 |
Aptevo Research And Development Llc |
Cd3结合多肽
|
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
|
SG10202008909VA
(en)
|
2016-03-24 |
2020-10-29 |
Bayer Pharma AG |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
WO2017216028A1
(en)
|
2016-06-15 |
2017-12-21 |
Bayer Pharma Aktiengesellschaft |
Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
|
|
US12059472B2
(en)
|
2016-12-21 |
2024-08-13 |
Bayer Aktiengesellschaft |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
US11433140B2
(en)
|
2016-12-21 |
2022-09-06 |
Bayer Pharma Aktiengesellschaft |
Specific antibody drug conjugates (ADCs) having KSP inhibitors
|
|
AU2017380871C1
(en)
|
2016-12-21 |
2025-05-15 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (ADCs) having enzymatically cleavable groups
|
|
KR20200130709A
(ko)
|
2018-03-06 |
2020-11-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
전립선-특이 막 항원 car 및 이의 사용 방법
|
|
CN112469440B
(zh)
|
2018-06-18 |
2024-09-06 |
优瑞科生物技术公司 |
靶向前列腺特异性膜抗原(psma)的构建体和其用途
|
|
EP3830132B1
(en)
|
2018-07-31 |
2022-11-23 |
Heidelberg Pharma Research GmbH |
Humanized antibodies against psma
|